Our client was a publicly-traded clinical-stage pharmaceutical company, which specialized in drug formulation and delivery technology innovation. Its lead development drug was an inhaled nasal powder in a custom-made dispenser, in late-stage clinical trials for the treatment of acute pain. With a planned US launch of what would be their first commercial product, the company asked Alacrita to review the readiness of the product supply chain and to make recommendations to address any gaps identified.


The Alacrita team of supply chain and commercialization experts first conducted a situational analysis of the existing supply chain components and processes. We interviewed members of the client management team in key functions, including CMC, Quality Assurance, Regulatory, Program Management, Commercial, Market Access, IT, Finance and Legal. We proposed the structure, headcount and roles for a Supply Chain team to support the product launch. Based on the needs of the company and product, we also recommended a shortlist of suitable 3rd-Party Logistics providers for the client to engage for the product launch.

Alacrita also recommended that the client perform a rigorous risk assessment of the upstream supply chain for the product, to understand the key threats to security of product supply and to map out mitigation steps.


Upstream & downstream supply chain consulting

As a component of commercial launch planning activities, Alacrita consultants help our clients get their product to customers in key geographic markets, by providing expertise in strategic and tactical design, as well as the legal, financial and practical setup, of pharmaceutical supply chains. Our experts will help you build a patient-oriented supply chain that balances the needs of the patient, the providers, the market and the company, in compliance of local regulations. 

Learn more

Related Case Studies